tirzepatide muscle loss Is Causing Loss? Inside the SURMOUNT-1 Sub-Study | Dr. Dan Tirzepatide for Medical Weight Loss

This indication diversification insulates GLP-1 manufacturers from reimbursement pressure in any single category while creating cross-indication pricing power

While lean mass typically accounts for about one-quarter of total weight lost, this pattern is comparable to other weight-loss approaches and not uniquely harmful

Semaglutide and similar GLP-1 medications already cause significant changes to your digestive system, including slowed gastric emptying and reduced appetite

The earliest retatrutide could become commercially available is late 2027 or 2028, assuming Phase 3 trials complete successfully and regulatory approvals proceed without delays